Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis

Journal of Hepatology

Volumn 62, Issue 3, 2015, Pages 682-689

  Bardou Jacquet, Edouard ^a,b   Morcet, Jeff ^c   Manet, Ghislain ^c   Lainé, Fabrice ^a,c   Perrin, Michèle ^c   Jouanolle, Anne Marie ^a   Guyader, Dominique ^a,b,d   Moirand, Romain ^a,b,d   Viel, Jean François ^c,d   Deugnier, Yves ^a,b,c,d  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Cancer; Cardiovascular disease; Hemochromatosis; HFE; Iron overload; Survival

Indexed keywords

HFE PROTEIN; IRON; TRANSFERRIN; FERRITIN; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN;

ADDISON DISEASE; ADULT; AGE; ALCOHOL CONSUMPTION; ALCOHOL INTOXICATION; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CACHEXIA; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COLON CANCER; CORONARY ARTERY DISEASE; DEATH CERTIFICATE; DEMENTIA; DIABETES MELLITUS; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GENE MUTATION; HEART VALVE REPLACEMENT; HEMOCHROMATOSIS; HOMOZYGOTE; HUMAN; INHALATION; KIDNEY CANCER; KIDNEY FAILURE; LIVER CANCER; LIVER DISEASE; LIVER FIBROSIS; LUNG CANCER; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NONALCOHOLIC FATTY LIVER; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PYELONEPHRITIS; SKIN CANCER; STANDARDIZED MORTALITY RATIO; SUICIDE; AMINO ACID SUBSTITUTION; BLOOD; CARDIOVASCULAR DISEASES; EPIDEMIOLOGY; FRANCE; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY;

ADULT; AMINO ACID SUBSTITUTION; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; FEMALE; FERRITINS; FRANCE; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMOZYGOTE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TRANSFERRIN;

EID: 84923032036     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.10.025     Document Type: Article

References (27)

1. C. Niederau, R. Fischer, A. Sonnenberg, W. Stremmel, H.J. Trampisch, and G. Strohmeyer Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis N Engl J Med 313 1985 1256 1262
2. P. Brissot, R. Moirand, A.M. Jouanolle, D. Guyader, J.Y. Le Gall, and Y. Deugnier A genotypic study of 217 unrelated probands diagnosed as "genetic hemochromatosis" on "classical" phenotypic criteria J Hepatol 30 1999 588 593
3. B.R. Bacon, J.K. Olynyk, E.M. Brunt, R.S. Britton, and R.K. Wolff HFE genotype in patients with hemochromatosis and other liver diseases Ann Intern Med 130 1999 953 962
4. D.H. Crawford, E.C. Jazwinska, L.M. Cullen, and L.W. Powell Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation Gastroenterology 114 1998 1003 1008
5. R. Moirand, A.M. Jouanolle, P. Brissot, J.Y. Le Gall, V. David, and Y. Deugnier Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives Gastroenterology 116 1999 372 377
6. K.J. Allen, L.C. Gurrin, C.C. Constantine, N.J. Osborne, M.B. Delatycki, and A.J. Nicoll Iron-overload-related disease in HFE hereditary hemochromatosis N Engl J Med 358 2008 221 230
7. E. Beutler, V.J. Felitti, J.A. Koziol, N.J. Ho, and T. Gelbart Penetrance of 845G - > A (C282Y) HFE hereditary haemochromatosis mutation in the USA Lancet 359 2002 211 218
8. A.L. Fracanzani, A. Piperno, L. Valenti, M. Fraquelli, S. Coletti, and A. Maraschi Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors Hepatology 51 2010 501 510
9. C. Niederau, R. Fischer, A. Purschel, W. Stremmel, D. Haussinger, and G. Strohmeyer Long-term survival in patients with hereditary hemochromatosis Gastroenterology 110 1996 1107 1119
10. N. Milman, P. Pedersen, T. a Steig, K.E. Byg, N. Graudal, and K. Fenger Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients Ann Hematol 80 2001 737 744
11. M. Elmberg, R. Hultcrantz, F. Ebrahim, S. Olsson, S. Lindgren, and L. Loof Increased mortality risk in patients with phenotypic hereditary hemochromatosis but not in their first-degree relatives Gastroenterology 137 2009 1301 1309
12. R.V. Andersen, A. Tybjaerg-Hansen, M. Appleyard, H. Birgens, and B.G. Nordestgaard Hemochromatosis mutations in the general population: iron overload progression rate Blood 103 2004 2914 2919
13. J.S. Pankow, E. Boerwinkle, P.C. Adams, E. Guallar, C. Leiendecker-Foster, and J. Rogowski HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study Transl Res 152 2008 3 10
14. J.C. Barton, R.T. Acton, J. So, S. Chan, and P.C. Adams Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 mug/L at diagnosis Clin Gastroenterol Hepatol 10 2012 412 416
15. P. Bedossa, and T. Poynard An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology 24 1996 289 293
16. D. Guyader, C. Jacquelinet, R. Moirand, B. Turlin, M.H. Mendler, and J. Chaperon Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis Gastroenterology 115 1998 929 936
17. R. Moirand, P.C. Adams, V. Bicheler, P. Brissot, and Y. Deugnier Clinical features of genetic hemochromatosis in women compared with men Ann Intern Med 127 1997 105 110
18. T.P. Tuomainen, K. Kontula, K. Nyyssonen, T.A. Lakka, T. Helio, and J.T. Salonen Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: a prospective cohort study in men in eastern Finland Circulation 100 1999 1274 1279
19. M.F. Engberink, C.M. Povel, J. Durga, D.W. Swinkels, W.L. de Kort, and E.G. Schouten Hemochromatosis (HFE) genotype and atherosclerosis: increased susceptibility to iron-induced vascular damage in C282Y carriers? Atherosclerosis 211 2010 520 525
20. M. Jehn, J.M. Clark, and E. Guallar Serum ferritin and risk of the metabolic syndrome in U.S. adults Diabetes Care 27 2004 2422 2428
21. L. Valenti, D.W. Swinkels, L. Burdick, P. Dongiovanni, H. Tjalsma, and B.M. Motta Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease Nutr Metab Cardiovasc Dis 21 2011 568 575
22. J.L. Sullivan Do hemochromatosis mutations protect against iron-mediated atherogenesis? Circ Cardiovasc Genet 2 2009 652 657
23. C. Garuti, Y. Tian, G. Montosi, M. Sabelli, E. Corradini, and R. Graf Hepcidin expression does not rescue the iron-poor phenotype of Kupffer cells in Hfe-null mice after liver transplantation Gastroenterology 139 2010 e311
24. P.J. Kraml, R.L. Klein, Y. Huang, A. Nareika, and M.F. Lopes-Virella Iron loading increases cholesterol accumulation and macrophage scavenger receptor I expression in THP-1 mononuclear phagocytes Metabolism 54 2005 453 459
25. A.L. Fracanzani, D. Conte, M. Fraquelli, E. Taioli, M. Mattioli, and A. Losco Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease Hepatology 33 2001 647 651
26. N.J. Osborne, L.C. Gurrin, K.J. Allen, C.C. Constantine, M.B. Delatycki, and C.E. McLaren HFE C282Y homozygotes are at increased risk of breast and colorectal cancer Hepatology 51 2010 1311 1318
27. L.R. Zacharski, B.K. Chow, P.S. Howes, G. Shamayeva, J.A. Baron, and R.L. Dalman Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial J Natl Cancer Inst 100 2008 996 1002